作者: Masao Tanaka
DOI: 10.1016/J.HPB.2016.06.014
关键词: High rate 、 Intraductal papillary mucinous neoplasm 、 Medicine 、 Asymptomatic 、 Expert consensus 、 General surgery 、 Malignancy 、 Main duct 、 Branch Duct 、 Pancreas 、 Hepatology 、 Gastroenterology
摘要: Since very little high-level evidence exists in the management of intraductal papillary mucinous neoplasm (IPMN) pancreas, all guidelines currently available are based on expert consensus. Nonetheless, international consensus issued 2006 by International Association Pancreatology (Sendai guidelines)1 and revised 2012 (Fukuoka guidelines) well accepted worldwide widely utilized clinical practice.2, 3, 4, 5 Few controversies remain regarding main duct IPMN (MD-IPMN) given high rate underlying malignancy. However, for branch (BD-IPMN), surgical indications a topic debate, since average malignancy is only 26% such cases resected.6, 7